CEL-SCI, Saudi Amarox partner to commercialize Multikine in Saudi Arabia

CEL-SCI Corporation

CEL-SCI Corporation

CVM

0.00
  • CEL-SCI set a strategic agreement with Saudi Amarox to commercialize and distribute Multikine in Saudi Arabia.
  • Signing ceremony scheduled for June 22, 2026 at BIO 2026 in San Diego.
  • Agreement terms include a 50%/50% revenue share for Saudi sales upon receipt of Breakthrough Medicine Designation.
  • Amarox to serve as local regulatory representative, lead Saudi-FDA interactions, become exclusive distributor upon SFDA approval.
  • Amarox holds an option to expand the arrangement to Gulf Cooperation Council markets following Saudi approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260612660219) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.